Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.